Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury
Yıl: 2019 Cilt: 13 Sayı: 6 Sayfa Aralığı: 475 - 480 Metin Dili: İngilizce DOI: 10.12956/tchd.592543 İndeks Tarihi: 25-06-2021
Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury
Öz: Objective: Increased levels of Angiotensin II (Ang II) are responsible for the development of hypertension and diabetesinduced nephropathy. In addition, the preventability of renal fibrosis with Ang II blockade is a known entity. Althoughmast cells are not present in normal kidney, increased mast cell density in the specimens examined for fibrosis hasattracted attention and it is thought that fibrotic agents released from these cells and may contribute to the process.Therefore, an experimental study was planned to decrease the ang II levels with captopril, an angiotensin convertingenzyme (ACE) inhibitor and to prevent the development of renal scarring due to pyelonephritis using ketotifen, a mastcell stabilizer.Material and Methods: Fifty rats were divided into five equal groups. In Group A, the renal cortex was injected withSF. In Group B, acute pyelonephritis was induced by 107 E. coli injections into the renal cortex. Group C receivedantibiotic treatment with E. coli injection, Group D received antibiotic and captopril with E. coli injection, Group E.received antibiotic and ketotifen with E. coli injection. In order to represent the chronic process, rats were sacrificed after6 weeks, and the contralateral kidney was included in pathological examination and statistical evaluation.Results: Inflammatory scores were significantly higher in group B compared to group A (p = 0.001). Captopril orketotifen treatment were the only factors that reduced scar development (p = 0.007). However, when captopril orketotifen treatments were compared in preventing scar development, no superiority was found (p> 0.05).Conclusion: We found that captopril and ketotifen has a protective effect in the development of renal fibrosis in a ratmodel of acute pyelonephritis. We believe that our study may contribute to clinical trials in the prevention of renal scardevelopment.
Anahtar Kelime: Piyelonefrit Hasarına Bağlı Gelişen Böbrek Skarının Önlenmesinde Kaptopril ve Ketotifenin Etkisi
Öz: Amaç: Hipertansiyon ve diabete bağlı nefropati gelişiminden artmış Angiotensin II (Ang II) düzeyleri sorumlu tutulmaktadır. Bunun yanı sıra Ang II blokajı ile renal fibrozis gelişiminin önlenebilirliği bilinen bir antitedir. Böbrek dokusunun doğal bir elemanı olmamasına rağmen fibrosis nedeniyle incelenen spesmenlerde artmış mast hücre yoğunluğu dikkati çekmiş ve bu hücrelerden salınan fibrotik ajanların sürece katkıda bulunabileceği düşünülmüştür. Bu nedenle Ang II düzeylerinin bir anjiotensin converting enzim (ACE) inhibitörü olan kaptopril ile düşürülmesi ve yine bir mast hücre stabilizatörü olan ketotifenin kullanımı ile pyelonefrrite bağlı böbrek skarı gelişiminin önlenebilirliği hakkında deneysel çalışma planlandı. Gereç ve Yöntemler: Elli rat beş eşit gruba bölündü. Grup A’da renal kortekse SF enjeksiyonu yapıldı. Grup B’de renal kortekse 107 E. coli enjeksiyonu ile akut pyelonefrit oluşturuldu. Grup C’de E. coli enjeksiyonu ile beraber antibiyotik tedavisi, Grup D’de E. coli enjeksiyonu ile antibiyotik ve kaptopril uygulaması, Grup E’de E. coli enjeksiyonu ile antibiyotik ve ketotifen verildi. Kronik süreci temsil etmek amacı ile ratlar altı hafta sonra sakrifiye edildi, karşı böbrek de patolojik inceleme ve istatistiksel değerlendirmeye alındı. Bulgular: Grup B’de inflamatuar skorların A grubuna (sham) göre istatistiksel olarak anlamlı arttığı görüldü (p= 0.001). Skar gelişimini azaltan tek faktörün ise kaptopril ya da ketotifen tedavisi olduğu görüldü (p= 0.007). Ancak kaptopril ya da ketotifen tedavilerinin; skar gelişiminin önlenmesi açısından birbirlerine üstünlükleri saptanmadı (p>0.05).Sonuç: Ratlarda pyelonefrit modelinde kaptopril veya ketotifen tedavisinin renal fibrozis gelişimini önleyici etkisi mevcuttur. Çalışmamızın renal skar gelişimin önlenmesinde klinik çalışmalar için katkı sağlayabileceği düşüncesindeyiz.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Shortliffe LMD. Infection and Inflammation of Pediatric Genitourinary Tract. 10th Edition, In Philadelphia, Elsevier Saunders: CambellWalsh Urology 2012.
- 2. Lin R. Vesicoureteral reflux and urinary tract infection evolving practices and current controversies in pediatric imaging. AJR Am J Roentgenol 2009;192:1197-1208
- 3. Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013;169:477-92.
- 4. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-87.
- 5. Youxia Liu, Xinxin Ma, Jie Zheng , Junya Jia and Tiekun Yan. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrology 2017:18:206.
- 6. Lama G, Salsano M E, Pedulla M, Grassia C, Ruocco G. Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up. Pediatr Nephrol 1997; 11;714-8.
- 7. Kitao T, Kimata T, Yamanouchi S, Kato S, Tsuji S, Kaneko K. Urinary Biomarkers for Screening for Renal Scarring in Children with Febrile Urinary Tract Infection: Pilot Study. J Urol 2015;194:766-71.
- 8. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
- 9. Yamada M, Ueda M, Naruko T, Tanabe S, Han YS, Ikura Y, Ogami M, Takai S, Miyazaki M. Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int 2001;59:1374- 81.
- 10. Li Y, Liu FY, Peng YM, Li J, Chen J. Mast cell, a promising therapeutic target in tubulointerstitial fibrosis. Med Hypotheses 2007;69:99 - 103.
- 11. Wu Y, Liu Z, Hu W, Li L. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy. Hum Exp Toxicol 2005;24:41 - 7.
- 12. Dai H, Korthuis RJ. Mast Cell Proteases and Inflammation. Drug Discov Today Dis Models 2011;8:47 - 55.
- 13. Columbo M, Horowitz EM, Botana LM, McGlashan DW Jr, Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 1992;149: 599 – 608.
- 14. Kondo S, Kagami S, Kido H, Strutz F, Müller GA, Kuroda Y. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol 2001;12:1668 - 76.
- 15. Singal AK, Bajpai M, Dinda AK. Blockade of Renin-Angiotensin system blunts the fibrotic response in experimental acute pyelonephritis. J Indian Assoc Pediatr Surg/ Jan-Mar 2005/vol 10/ Issue 1:20 - 24
- 16. Abareshi A, Norouzi F, Asgharzadeh F, Beheshti F, Hosseini M, Farzadnia M, Khazaei M. Effect of Angiotensin-converting Enzyme Inhibitor on Cardiac Fibrosis and Oxidative Stress Status in Lipopolysaccharide-induced Inflammation Model in Rats. Int J Prev Med 2017;8:69.
- 17. Hrenák J, Arendášová K, Rajkovičová R, Aziriová S, Repová K, Krajčírovičová K, et al. Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats. Physiol Res 2013;62:S181 - 9.
- 18. Kostan W Reisinger, Jacco J de Haan, and Marc H Schreinemacher. Word of caution before implementing ketotifen for gastrointestinal transit improvement. World J Gastroenterol 2013;19: 4445 – 6.
- 19. Yukselen V, Karaoglu AO, Ozutemiz O, Yenisey C, Tuncyurek M. Ketotifen ameliorates development of fibrosis in alkali burns of the esophagus. Pediatr Surg Int 2004;20:429 - 33.
- 20. Emamghorashi F, Owji SM, Motamedifar M. Evaluation of Effectiveness of Vitamins C and E on Prevention of Renal Scar due to Pyelonephritis in Rat. Adv Urol 2011; 2011:489496.
- 21. Roupakias S, Sinopidis X, Karatza A, Varvarigou A. Predictive risk factors in childhood urinary tract infection, vesicoureteral reflux, and renal scarring management. Clin Pediatr (Phila) 2014;53:1119 - 33.
- 22. Smith EA. Pyelonephritis, renal scarring, and reflux nephropathy: a pediatric urologist’s perspective. Pediatr Radiol 2008;38:S76 - 82.
- 23. Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 2000;53:858 - 62.
| APA | azili m, KARAKUŞ E, Şenaylı A, Tiryaki T (2019). Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. , 475 - 480. 10.12956/tchd.592543 |
| Chicago | azili mujdem nur,KARAKUŞ ESRA,Şenaylı Atilla,Tiryaki Tugrul Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. (2019): 475 - 480. 10.12956/tchd.592543 |
| MLA | azili mujdem nur,KARAKUŞ ESRA,Şenaylı Atilla,Tiryaki Tugrul Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. , 2019, ss.475 - 480. 10.12956/tchd.592543 |
| AMA | azili m,KARAKUŞ E,Şenaylı A,Tiryaki T Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. . 2019; 475 - 480. 10.12956/tchd.592543 |
| Vancouver | azili m,KARAKUŞ E,Şenaylı A,Tiryaki T Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. . 2019; 475 - 480. 10.12956/tchd.592543 |
| IEEE | azili m,KARAKUŞ E,Şenaylı A,Tiryaki T "Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury." , ss.475 - 480, 2019. 10.12956/tchd.592543 |
| ISNAD | azili, mujdem nur vd. "Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury". (2019), 475-480. https://doi.org/10.12956/tchd.592543 |
| APA | azili m, KARAKUŞ E, Şenaylı A, Tiryaki T (2019). Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. Türkiye Çocuk Hastalıkları Dergisi, 13(6), 475 - 480. 10.12956/tchd.592543 |
| Chicago | azili mujdem nur,KARAKUŞ ESRA,Şenaylı Atilla,Tiryaki Tugrul Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. Türkiye Çocuk Hastalıkları Dergisi 13, no.6 (2019): 475 - 480. 10.12956/tchd.592543 |
| MLA | azili mujdem nur,KARAKUŞ ESRA,Şenaylı Atilla,Tiryaki Tugrul Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. Türkiye Çocuk Hastalıkları Dergisi, vol.13, no.6, 2019, ss.475 - 480. 10.12956/tchd.592543 |
| AMA | azili m,KARAKUŞ E,Şenaylı A,Tiryaki T Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. Türkiye Çocuk Hastalıkları Dergisi. 2019; 13(6): 475 - 480. 10.12956/tchd.592543 |
| Vancouver | azili m,KARAKUŞ E,Şenaylı A,Tiryaki T Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. Türkiye Çocuk Hastalıkları Dergisi. 2019; 13(6): 475 - 480. 10.12956/tchd.592543 |
| IEEE | azili m,KARAKUŞ E,Şenaylı A,Tiryaki T "Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury." Türkiye Çocuk Hastalıkları Dergisi, 13, ss.475 - 480, 2019. 10.12956/tchd.592543 |
| ISNAD | azili, mujdem nur vd. "Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury". Türkiye Çocuk Hastalıkları Dergisi 13/6 (2019), 475-480. https://doi.org/10.12956/tchd.592543 |
